Healthcare Industry News:  Longport 

Devices Wound Care

 News Release - March 12, 2008

Longport, Inc. Announces Sale of Scanners to National Long Term Care Group

GLEN MILLS, Pa.--(HSMN NewsFeed)--Longport, Inc. (OTC PK:LPTI), a medical technology specialist in high frequency high resolution ultrasound imaging, today announced the sale of thirteen (13) EPISCAN units to a commercial operator of senior care facilities. These EPISCAN units are going to be used for the early detection, documentation, and prevention of pressure ulcers in the group’s skilled nursing facilities.

Longport has been conducting a study with the purchasing group for the last two years, and the impressive results have led them to make this purchase. The study was conducted in three Montana nursing homes. The principal investigator of this study, Dr. Karen Zulkowski, explored the use of Longport’s EPISCAN I-200 for improved clinical detection of pressure ulcer risk and development. Dr. Zulkowski is a professor of nursing at Montana State University-Bozeman. Provisional results from the study were presented at the 2007 Symposium on Advanced Wound Care and at a workshop held as part of the Advances in Skin and Wound Care Conference in October 2007.

Dr. Zulkowski said “Study results demonstrated that 90% of people come into a nursing home with deep tissue skin changes at their heels and 60% have deep tissue changes at their sacrum. The EPISCAN I-200 shows these changes even before they are visible at the skin surface. This technology will allow the facilities to begin care planning earlier and increase quality of care for their residents. I hope all levels of care including acute care and rehabilitation facilities will also adopt the technology so that risk assessment is comprehensive and prevention is started earlier and is individualized to meet each patient’s needs.”

The EPISCAN will be used as part of the facilities’ admission process and for regular ongoing skin assessment protocols. Installation of the units is expected to commence in approximately one month.

Paul Wilson, President of Longport, Inc. said “We are pleased to report the order is a direct result of the positive feedback received from the study sites where the EPISCAN has been in use for the last two years. With this sale, Longport has sold a total of twenty (20) units so far this year. The first quarter of 2008 has been extremely promising and we are confident that sales will continue to grow as the year progresses.”

About Longport, Inc.

Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology company that specializes in high resolution ultrasound imaging. After several years and a multi-million dollar investment in the technology, Longport has secured patents, copyrights, and FDA permission to market. The Company’s technology has been used to engineer a unique high resolution ultrasound imaging system. For further information please contact Longport, Inc. at 1-800-289-6863 or visit our website at

Forward-looking Information and the Private Securities Litigation Reform Act of 1995

Certain statements in this press release, including statements concerning product development milestones and anticipated events, are “forward-looking statements” within the Private Litigation Reform Act of 1995. Forward Looking Statements are based on the opinions and estimates of management at the time the statements are made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. The words “believe,” “expect,” ”intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect Longport’s actual results include, among others, uncertainties as to the Company’s ability to manage potential problems, delays or anticipated expenses, including problems, delays or expenses involving manufacturing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only to the date of this release. Reference is made to Longport’s 2004 annual report on Form 10-K filed with the Securities and Exchange Commission for a more definitive description of such factors. Longport, Inc. undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

Source: Longport

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.